
    
      The primary objective of this study is to assess the safety of Remsima™ by evaluation of
      Events of Special Interest (ESI) in IBD patients, who have active Crohn's disease (CD),
      fistulizing Crohn's disease (CD), or Ulcerative Colitis (UC) for up to 5 years for each
      patient.

      The secondary objectives of this study are to evaluate additional safety and efficacy of
      Remsima™ in IBD patients, who have active CD, fistulizing CD or UC. Health-economic
      parameters will also be assessed
    
  